Memorial University of Newfoundland (MUN) and Medical Director (Rheumatology), Nexus Clinical Research, 120 Stavanger Drive, Suite 102, St. John's, NL, A1A 5E8, Canada.
Ther Adv Musculoskelet Dis. 2014 Oct;6(5):159-68. doi: 10.1177/1759720X14551567.
Abatacept is recommended by several expert consensus groups including the 2013 update of the EULAR recommendations for the pharmacologic management of rheumatoid arthritis (RA), as a potential choice for biologic therapy for patients with RA. Initially developed, studied, and approved as an intravenous (IV) formulation, abatacept is now also available as a subcutaneous (SC) injection. Having both options available makes abatacept a particularly versatile agent for the management of RA, greatly expanding the population of patients who could benefit from this treatment. This review provides a summary of the most important clinical trials that have investigated this molecule in both of its formulations, with a focus on the more recent trials evaluating the SC formulation, specifically the AMPLE study, the first major trial evaluating two biologic agents (abatacept and the tumor necrosis factor (TNF)-inhibitor adalimumab) in a head-to-head manner. In that study, SC abatacept was found to have an efficacy profile similar to that of SC adalimumab, both in combination with methotrexate.
阿巴西普被包括 2013 年 EULAR 类风湿关节炎（RA）药物治疗建议更新在内的多个专家共识组推荐，作为 RA 生物治疗的潜在选择。阿巴西普最初被开发、研究和批准为静脉（IV）制剂，现在也可作为皮下（SC）注射剂使用。这两种制剂都有，使得阿巴西普成为治疗 RA 的一种特别多功能药物，极大地扩大了可从这种治疗中受益的患者群体。这篇综述总结了研究这两种制剂的最重要的临床试验，重点是最近评估 SC 制剂的临床试验，特别是 AMPLE 研究，这是首次评估两种生物制剂（阿巴西普和肿瘤坏死因子（TNF）抑制剂阿达木单抗）头对头的主要试验。在该研究中，与甲氨蝶呤联合使用时，SC 阿巴西普的疗效与 SC 阿达木单抗相似。
